title: Allergen immunotherapy: what's new, what's next?
abstract: Although three sublingual immunotherapy tablets have been approved in the USA and more are under study, it is not clear that sublingual immunotherapy tablets will answer the needs of many patients in the USA, and this is due to the limited number of allergens that will be offered. Alternatives that employ off-label, currently available extracts hold the greatest likelihood of entering the US allergy practice. Those approaches that employ recombinant technology to produce hypoallergenic products face a long and expensive pathway to approval. Which of the many approaches under study will make it to the market is presently not clear.
authors.affiliation: National Jewish Health, 1400 Jackson Street, Denver, CO 80206, USA.
authors.forename: Harold S
authors.initials: HS
authors.lastname: Nelson
mesh_terms: D000286:Administration, Sublingual; D000485:Allergens / Q000008:administration & dosage / Q000276:immunology*; D017277:Drug Approval; D006801:Humans; D006967:Hypersensitivity / Q000276:immunology* / Q000628:therapy*; D063729:Sublingual Immunotherapy / Q000379:methods*; D013607:Tablets; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000485:Allergens; D013607:Tablets
keywords: epicutaneous; immunotherapy; intradermal; intralymphatic; recombinant technology; subcutaneous; sublingual